Masimo Co. (NASDAQ:MASI) CEO Joe E. Kiani sold 126,927 shares of Masimo stock in a transaction dated Friday, August 31st. The stock was sold at an average price of $117.85, for a total value of $14,958,346.95. Following the sale, the chief executive officer now owns 236,061 shares in the company, valued at approximately $27,819,788.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of NASDAQ MASI traded up $2.21 during midday trading on Tuesday, reaching $120.10. 470,700 shares of the company were exchanged, compared to its average volume of 528,512. Masimo Co. has a 1 year low of $80.69 and a 1 year high of $120.45. The firm has a market cap of $6.10 billion, a P/E ratio of 49.04, a P/E/G ratio of 2.75 and a beta of 1.02.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Wednesday, August 1st. The medical equipment provider reported $0.73 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.71 by $0.02. Masimo had a return on equity of 21.49% and a net margin of 15.30%. The firm had revenue of $211.62 million for the quarter, compared to analyst estimates of $207.85 million. During the same quarter last year, the company posted $0.83 earnings per share. The business’s revenue was up 10.0% on a year-over-year basis. equities analysts forecast that Masimo Co. will post 2.9 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MASI. Mount Yale Investment Advisors LLC purchased a new position in shares of Masimo during the first quarter worth about $101,000. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Masimo during the second quarter worth about $109,000. Cerebellum GP LLC purchased a new position in shares of Masimo during the second quarter worth about $173,000. US Bancorp DE grew its holdings in shares of Masimo by 36.9% during the second quarter. US Bancorp DE now owns 1,980 shares of the medical equipment provider’s stock worth $193,000 after buying an additional 534 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC purchased a new position in shares of Masimo during the first quarter worth about $202,000. 83.27% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts have recently commented on the company. Stifel Nicolaus lifted their target price on Masimo from $108.00 to $112.00 and gave the stock a “buy” rating in a research report on Thursday, August 2nd. BidaskClub upgraded Masimo from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 17th. ValuEngine upgraded Masimo from a “hold” rating to a “buy” rating in a research report on Monday, May 7th. Finally, Zacks Investment Research upgraded Masimo from a “hold” rating to a “buy” rating and set a $110.00 target price on the stock in a research report on Tuesday, July 3rd. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $102.60.

Masimo Company Profile

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Further Reading: What does EPS mean?

Insider Buying and Selling by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.